Biohaven Ltd. has announced the presentation of clinical safety and efficacy data for BHV-1510, a next-generation Trop2 antibody drug conjugate $(ADC)$, in combination with the anti-PD-1 monoclonal antibody cemiplimab. The results were presented at the 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress held from December 10-12, 2025, in London, United Kingdom. In a Phase 1 trial involving pretreated patients with advanced or metastatic cancer, including those with prior PD-$(L)$1 treatment, the combination of BHV-1510 and cemiplimab demonstrated confirmed objective response rates of 60% in non-small cell lung cancer (NSCLC), 100% in endometrial cancer, and 50% in urothelial cancer. The safety profile showed low rates of adverse events attributed to the unconjugated payload, with no cases of interstitial lung disease reported. The poster presentation is available on Biohaven's website.